唑来膦酸治疗癌症骨转移疼痛临床观察  

Clinical study on zoledronate for treatment of bone metastatis

作　　者：赵翌[1] 李颖[1] 白松[1] 高亚杰[1] 刘基巍[1] 

机构地区：[1]大连医科大学附属第一医院肿瘤科,大连116011

出　　处：《癌症进展》2005年第4期395-398,共4页Oncology Progress

摘　　要：目的探讨唑来膦酸治疗恶性肿瘤骨转移疼痛的疗效和安全性。方法选择恶性肿瘤骨转移中、重度疼痛患者52例,随机双盲分成两组A组(试验组)22例唑来膦酸4mg溶于生理盐水50ml静滴;B组(对照组)30例博宁90mg+生理盐水750ml静滴。结果唑来膦酸镇痛效果显效(CR)422,部分缓解(PR)1322,无效(NR)522,总有效率(CR+PR)77.27%(1722),疗效维持时间16.4天,KPS评分平均提高20分,主要不良反应为一过性骨痛加重,发热、恶心、呕吐。对照组总有效率(RR)77.33%,疗效维持时间14.8天。结论唑来膦酸对缓解癌症骨转移疼痛有效,安全性好,病人可耐受。Objective To observe and evaluate the efficancy and safety of zolendronate in the pain patients with bone metastatis.Methods 52 patients were randomizedly divided into two groups(A and B).Group A(the experimental group,22cases)was treated with zoledronate 4mg+NS 50ml,intravenously;Group B(the control group,30 cases)was treated with pamidronate,90mg+NS 750ml,intravenously.Results The efficency of inhabitting of pain by zolendronate,CR:4/22;PR:13/22;NR:5/22;CR+PR:7/22,77.27%,and lasting 16.4 days,KPS increased by 20 scores.The main side-effects were more pain temporarily,fever,nausea,vomiting.The control group,RR:77.33%;lasting 14.8 days.Conclusion Zolendronate can release pain of cancer bone metastatis,and it is safety.

关 键 词：唑来膦酸 骨转移 

分 类 号：R738.1[医药卫生—肿瘤]